|
WO2004083432A1
(en)
*
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2523672C
(en)
|
2003-04-29 |
2012-07-17 |
Avi Biopharma, Inc. |
Compositions for enhancing transport of molecules into cells
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
CA2553104A1
(en)
*
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
HUE028632T2
(en)
|
2004-06-28 |
2016-12-28 |
Univ Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
CA2596506C
(en)
*
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
US8524676B2
(en)
*
|
2005-09-08 |
2013-09-03 |
Sarepta Therapeutics, Inc. |
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
ES2397441T5
(es)
|
2006-02-13 |
2022-09-14 |
Daiichi Sankyo Co Ltd |
Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20100016215A1
(en)
*
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
AU2008345033B2
(en)
*
|
2007-12-28 |
2014-04-03 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8231895B2
(en)
|
2008-05-22 |
2012-07-31 |
Universidade De Coimbra |
Targeted delivery to human diseases and disorders
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
EP2283029A1
(en)
*
|
2008-06-04 |
2011-02-16 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
IL313162A
(en)
|
2008-10-24 |
2024-07-01 |
Sarepta Therapeutics Inc |
Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
|
|
AU2009335740B2
(en)
*
|
2008-12-17 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
NZ626359A
(en)
|
2009-11-12 |
2016-02-26 |
Univ Western Australia |
Antisense molecules and methods for treating pathologies
|
|
TWI495473B
(zh)
|
2009-11-13 |
2015-08-11 |
Sarepta Therapeutics Inc |
反義抗病毒化合物及治療流感病毒感染的方法
|
|
WO2011071280A2
(ko)
*
|
2009-12-11 |
2011-06-16 |
광주과학기술원 |
세포내 타겟 결합용 바이포달 펩타이드 바인더
|
|
US9006415B2
(en)
*
|
2010-04-06 |
2015-04-14 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US9050373B2
(en)
*
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
KR101981705B1
(ko)
|
2010-05-28 |
2019-05-24 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
EP3031920B1
(en)
*
|
2010-07-19 |
2019-08-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
KR102229650B1
(ko)
*
|
2011-05-05 |
2021-03-19 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
펩타이드 올리고뉴클레오타이드 접합체
|
|
CN103998458B
(zh)
|
2011-08-30 |
2018-10-09 |
医学研究理事会 |
具有中央疏水域的细胞穿透肽
|
|
WO2013033407A2
(en)
|
2011-08-30 |
2013-03-07 |
The Regents Of The University Of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
EP2581448B1
(en)
*
|
2011-10-13 |
2015-01-28 |
Association Institut de Myologie |
Tricyclo-phosphorothioate DNA
|
|
PT2788487T
(pt)
|
2011-12-08 |
2018-07-03 |
Sarepta Therapeutics Inc |
Análogos de oligonucleótido visando lmna humano
|
|
EP4043039A1
(en)
*
|
2012-01-27 |
2022-08-17 |
BioMarin Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013173599A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
AU2013262649A1
(en)
*
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
AU2013262656A1
(en)
*
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating UTRN expression
|
|
EP2850182A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 GENE EXPRESSION
|
|
KR101329411B1
(ko)
*
|
2012-05-31 |
2013-11-14 |
주식회사 엘지생활건강 |
피부투과성 펩타이드
|
|
ES2723885T3
(es)
|
2012-07-19 |
2019-09-03 |
Daiichi Sankyo Co Ltd |
Anticuerpos anti-Siglec-15
|
|
CA3211094A1
(en)
|
2012-08-13 |
2014-02-20 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
AU2013323820B2
(en)
|
2012-09-25 |
2019-06-27 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
JP6452614B2
(ja)
|
2012-11-15 |
2019-01-16 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲート
|
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
|
AU2014236140B2
(en)
|
2013-03-14 |
2019-10-03 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
EP3662912B1
(en)
|
2013-03-15 |
2025-12-03 |
Sarepta Therapeutics, Inc. |
Improved dosages of eteplirsen for treating duchenne muscular dystrophy
|
|
EP3065783A4
(en)
*
|
2013-11-06 |
2017-06-21 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
US9790495B2
(en)
|
2014-05-16 |
2017-10-17 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
JP6687542B2
(ja)
|
2014-05-19 |
2020-04-22 |
オレゴン ステート ユニバーシティ |
アンチセンス抗菌化合物および方法
|
|
TWI787678B
(zh)
*
|
2014-05-23 |
2022-12-21 |
美商健臻公司 |
藉由使用反義寡核苷酸創造提前終止密碼子抑制或下調肝醣合成酶
|
|
BR112016027236A2
(pt)
|
2014-05-23 |
2017-10-17 |
Genzyme Corp |
porções de múltiplos oligonucleotídeos em veículo de peptídeo
|
|
JP6994941B2
(ja)
*
|
2014-12-31 |
2022-02-04 |
オレゴン ステート ユニバーシティ |
アンチセンス抗細菌性化合物および方法
|
|
MA41795A
(fr)
*
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
EP3302489A4
(en)
|
2015-06-04 |
2019-02-06 |
Sarepta Therapeutics, Inc. |
METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
|
|
BR112018007066A2
(pt)
*
|
2015-10-09 |
2018-10-23 |
Sarepta Therapeutics Inc |
composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
|
|
WO2017112885A1
(en)
|
2015-12-23 |
2017-06-29 |
David Greenberg |
Antisense antibacterial compounds and methods
|
|
AU2016379402B2
(en)
|
2015-12-23 |
2023-01-12 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
CA3021267A1
(en)
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
CA3022303A1
(en)
|
2016-04-29 |
2017-11-02 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human lmna
|
|
AU2017382741B2
(en)
*
|
2016-12-19 |
2025-01-30 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
AU2017382723B2
(en)
|
2016-12-19 |
2025-01-30 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
US10800817B2
(en)
*
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
KR102646318B1
(ko)
|
2016-12-19 |
2024-03-12 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
SG11201906200WA
(en)
|
2017-01-06 |
2019-08-27 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
US20180207293A1
(en)
*
|
2017-01-25 |
2018-07-26 |
2C Tech Corp. |
Nanoparticles for sustained ophthalmic drug delivery and methods of use
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
US20200248178A1
(en)
|
2017-09-28 |
2020-08-06 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
US20200254002A1
(en)
|
2017-09-28 |
2020-08-13 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
EP3687577A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
WO2019079386A1
(en)
*
|
2017-10-17 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
|
|
JP2021504315A
(ja)
|
2017-11-21 |
2021-02-15 |
ルジェニクス，インコーポレーテッド |
多形及びその使用
|
|
JP7013626B2
(ja)
*
|
2018-01-05 |
2022-02-01 |
国立医薬品食品衛生研究所長 |
細胞膜透過ペプチド、構築物、及び、カーゴ分子を細胞内に輸送する方法
|
|
US11987647B2
(en)
|
2018-05-09 |
2024-05-21 |
Ohio State Innovation Foundation |
Cyclic cell-penetrating peptides with one or more hydrophobic residues
|
|
EP3806868A4
(en)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
|
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
CA3108287A1
(en)
*
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
CA3122200A1
(en)
|
2018-12-07 |
2020-06-11 |
Oxford University Innovation Limited |
Linkers
|
|
IL283646B2
(en)
|
2018-12-13 |
2025-11-01 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
EP3955966A1
(en)
|
2019-04-18 |
2022-02-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
GB201911403D0
(en)
*
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
KR102270700B1
(ko)
*
|
2019-11-01 |
2021-06-30 |
한국과학기술연구원 |
폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
|
|
WO2021119397A1
(en)
|
2019-12-13 |
2021-06-17 |
Rgenix, Inc. |
Metal salts and uses thereof
|
|
CA3165961A1
(en)
|
2019-12-26 |
2021-07-01 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid that induces skipping of exon 50
|
|
MX2022010545A
(es)
|
2020-02-28 |
2022-09-21 |
Nippon Shinyaku Co Ltd |
Acidos nucleicos antisentido que inducen la omision del exon 51.
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
WO2022140535A1
(en)
|
2020-12-23 |
2022-06-30 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|
|
KR20240004609A
(ko)
|
2021-04-30 |
2024-01-11 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근이영양증에 대한 치료 방법
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
MX2023014417A
(es)
|
2021-06-23 |
2023-12-15 |
Nippon Shinyaku Co Ltd |
Combinacion de oligomeros antisentido.
|
|
JPWO2023282344A1
(enExample)
|
2021-07-08 |
2023-01-12 |
|
|
|
KR20240035502A
(ko)
|
2021-07-08 |
2024-03-15 |
니뽄 신야쿠 가부시키가이샤 |
신독성 경감제
|
|
US20240285770A1
(en)
|
2021-07-08 |
2024-08-29 |
Nippon Shinyaku Co., Ltd. |
Precipitation suppressing agent
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2023034515A2
(en)
*
|
2021-09-03 |
2023-03-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
US20250195667A1
(en)
|
2022-03-17 |
2025-06-19 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
JP2025512464A
(ja)
|
2022-04-15 |
2025-04-17 |
ダイン セラピューティクス，インコーポレーテッド |
筋緊張性ジストロフィーを処置するための筋標的化複合体および製剤
|
|
JP2025513521A
(ja)
|
2022-04-22 |
2025-04-24 |
エントラーダ セラピューティクス，インコーポレイティド |
治療薬を送達するための環状ペプチド
|
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
|
EP4612292A1
(en)
|
2022-11-02 |
2025-09-10 |
Sarepta Therapeutics, Inc. |
Formulation of an antisense oligomer conjugate
|
|
EP4634373A1
(en)
|
2022-12-16 |
2025-10-22 |
University of Rochester |
Repairment of barrier dysfunction in esophagus
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|